Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide
Share:
(Reuters) - Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by U.S. antitrust regulators, and pushed back the closing of their $74 billion (58 billion pounds) deal.The move sent Bristol's shares down nearly 7%, while Celgene's shares fell nearly 5%. The psoriasis drug, which brought in revenue of around $1.61 billion last year, is currently worth around $9.3 billion, according to a net present value calculation by Credit..